I apologize completely about posting the informati

I apologize completely about posting the information about Ebola. I have apparently offended several others because I didn't provide critical info on the company as opposed to data on what the company might be doing. I guess from my point of view it is clear that the future depends on the N-Assay outcomes (that I think are incredible in their potential). The packaging is quite important but its problem is that it cuts into something like 25% of the profit margin of the major companies because they have built into the pricing a 25-30% margin due to breakage and deterioration. If you wonder why the "brilliant" minds of the BIG companies have adopted the NNLX technology to the extent they have it is likely that at this point (early) their business models lose out from the shift. It is still an important development but faces a great deal of "friction". It isn't that the packaging and single assay tech isn't important but that it can be muted by the BIGs.

On the other hand, I think the N-Assay's market momentum is irresistible and am waiting for that as it unfolds in the near future. Please, only actual investors reply.